Key Decisions in HIV Care: Data on Long-Acting Injectable PrEP
Listen as Jason Schafer, PharmD, MPH, shares the latest data to support long-acting PrEP, including efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.
Decera Clinical Education Infectious Disease Podcast · Jason Schafer PharmD MPH
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Jason Schafer, PharmD, MPH, explores the data for long-acting injectable pre-exposure prophylaxis (PrEP).
Listen as he gives his perspectives on the:
- PrEP pipeline and the importance of having options for patients with differing preferences
- FDA approval of long-acting cabotegravir for PrEP
- HPTN 083 and 084 studies of long-acting cabotegravir for PrEP compared with oral emtricitabine/tenofovir disoproxil fumarate
- Safety data on long-acting cabotegravir for PrEP
- CDC recommendations on the management of injection-site reactions with cabotegravir for PrEP
Presenter:
Jason Schafer, PharmD, MPH
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania
Follow along with the slides at:
https://bit.ly/3tbvEPK
See the entire program at:
https://bit.ly/3q2DlGd
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.